公开(公告)号：US20240254164A1

公开(公告)日：2024-08-01

申请号：US18559251

申请日：2022-05-03

Applicant: DSM IP Assets B.V.

Inventor： Marc HEIDL ,  Thomas SCHAERER ,  Alexander SCHLIFKE-POSCHALKO

IPC: C07K5/083 ,  A61K8/64 ,  A61K38/00 ,  A61Q19/08

CPC classification number: C07K5/081 ,  A61K8/64 ,  A61Q19/08 ,  A61K38/00 ,  A61K2800/805

Abstract: The present invention relates to purification of a tripeptide of formula (I). By using said method, the tripeptide of formula (I) is obtained in a very pure form and due to this effect the purified tripeptide can be used in a variety of cosmetic and pharmaceutic compositions which are not accessible for the respective unpurified tripeptide.

公开(公告)号：US20240065990A1

公开(公告)日：2024-02-29

申请号：US18467645

申请日：2023-09-14

Applicant: Bellus Health Inc.

Inventor： Xianqi KONG ,  Mohamed ATFANI ,  Benoit BACHAND ,  Abderrahim BOUZIDE ,  Stephanie CIBLAT ,  Sophie LEVESQUE ,  David MIGNEAULT ,  Isabelle VALADE ,  Xinfu WU ,  Daniel DELORME

IPC: A61K31/145 ,  A61K47/54 ,  A61K47/64 ,  C07C309/15 ,  C07C309/18 ,  C07C309/19 ,  C07C309/24 ,  C07D207/16 ,  C07D209/20 ,  C07D217/24 ,  C07D233/64 ,  C07D285/36 ,  C07D285/38 ,  C07D291/02 ,  C07D317/40 ,  C07D323/02 ,  C07D333/24 ,  C07H7/02 ,  C07H15/12 ,  C07J9/00 ,  C07K5/062 ,  C07K5/068 ,  C07K5/083 ,  C12P11/00 ,  C12P13/00

CPC classification number: A61K31/145 ,  A61K47/54 ,  A61K47/542 ,  A61K47/545 ,  A61K47/549 ,  A61K47/554 ,  A61K47/64 ,  C07C309/15 ,  C07C309/18 ,  C07C309/19 ,  C07C309/24 ,  C07D207/16 ,  C07D209/20 ,  C07D217/24 ,  C07D233/64 ,  C07D285/36 ,  C07D285/38 ,  C07D291/02 ,  C07D317/40 ,  C07D323/02 ,  C07D333/24 ,  C07H7/02 ,  C07H15/12 ,  C07J9/005 ,  C07K5/06026 ,  C07K5/06052 ,  C07K5/0606 ,  C07K5/06069 ,  C07K5/06086 ,  C07K5/0806 ,  C07K5/081 ,  C12P11/00 ,  C12P13/001 ,  Y02P20/55

Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

公开(公告)号：US11779629B2

公开(公告)日：2023-10-10

申请号：US16999849

申请日：2020-08-21

Applicant: The University of British Columbia

Inventor： Neil R. Cashman

IPC: A61K38/00 ,  A61K38/17 ,  C07K7/00 ,  C07K5/12 ,  A61K38/07 ,  A61K38/12 ,  A61K39/385 ,  A61K47/64 ,  C07K14/47 ,  C07K5/117 ,  C07K7/06 ,  C07K7/64 ,  C12N5/16 ,  G01N33/68 ,  A61P25/28 ,  C07K16/18 ,  C07K5/083 ,  C07K5/087 ,  C07K5/09 ,  C07K5/093 ,  C07K5/097 ,  C07K5/113 ,  A61K39/00 ,  A61K51/08 ,  A61K49/18 ,  A61K45/00 ,  A61K39/395 ,  A61K38/05 ,  A61K51/10 ,  A61K47/68 ,  A61K38/08 ,  A61K39/39 ,  A61K45/06 ,  A61K47/69 ,  A61L31/10 ,  A61L27/34 ,  A61L29/16 ,  A61L31/16 ,  A61L29/08 ,  A61L27/22 ,  G01N33/50 ,  C07K5/103 ,  C07K14/435 ,  C12N5/10 ,  C07K7/08

CPC classification number: A61K38/07 ,  A61K38/12 ,  A61K39/385 ,  A61K47/643 ,  A61K47/646 ,  A61P25/28 ,  C07K5/081 ,  C07K5/0808 ,  C07K5/0812 ,  C07K5/0815 ,  C07K5/0819 ,  C07K5/0821 ,  C07K5/1021 ,  C07K5/1024 ,  C07K7/06 ,  C07K7/64 ,  C07K14/4711 ,  C07K16/18 ,  C12N5/16 ,  G01N33/6896 ,  A61K38/00 ,  A61K38/05 ,  A61K38/08 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39533 ,  A61K45/05 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6921 ,  A61K49/1818 ,  A61K49/1866 ,  A61K51/088 ,  A61K51/10 ,  A61K51/1018 ,  A61K2039/505 ,  A61K2039/55505 ,  A61K2039/6081 ,  A61K2300/00 ,  A61L27/227 ,  A61L27/34 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  C07K5/101 ,  C07K7/08 ,  C07K14/435 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C12N5/10 ,  G01N33/5058 ,  G01N2333/4709 ,  G01N2800/28 ,  G01N2800/2821 ,  G01N2800/387

Abstract: The disclosure pertains to methods of treating or preventing a disease or condition associated with and/or induced by soluble A-beta oligomer such as Alzheimer's disease by administering to a subject in need thereof conformation specific and/or selective antibodies or binding fragments thereof and related products.

公开(公告)号：US10041057B2

公开(公告)日：2018-08-07

申请号：US15000896

申请日：2016-01-19

Applicant: University of Wyoming

Inventor： Mark Gomelsky ,  Min-Hyung Ryu

IPC: C12N9/00 ,  C12N15/62 ,  A61K48/00 ,  A61N5/00 ,  G01N33/52 ,  C12N9/88 ,  C07K14/195 ,  A61K38/16 ,  A61K38/51 ,  A61K41/00 ,  A61N5/06 ,  A61K31/711 ,  A61K31/713 ,  C07K7/06 ,  C12N9/50 ,  C12N9/64 ,  G01N33/50

CPC classification number: C12N9/88 ,  A61K31/711 ,  A61K31/713 ,  A61K38/164 ,  A61K38/51 ,  A61K41/00 ,  A61K41/0038 ,  A61K48/00 ,  A61N5/062 ,  A61N2005/0659 ,  C07K5/0606 ,  C07K5/081 ,  C07K5/0817 ,  C07K5/1013 ,  C07K7/06 ,  C07K7/08 ,  C07K14/195 ,  C07K2319/00 ,  C07K2319/60 ,  C12N9/50 ,  C12N9/6472 ,  C12N9/6475 ,  C12N15/62 ,  C12Y114/14 ,  C12Y304/22056 ,  C12Y406/01001 ,  C12Y406/01002 ,  G01N33/5023 ,  G01N33/5088

Abstract: Methods and constructs are provided for controlling processes in live animals, plants or microbes via genetically engineered near-infrared light-activated or light-inactivated proteins including chimeras including the photosensory modules of bacteriohytochromes and output modules that possess enzymatic activity and/or ability to bind to DNA, RNA, protein, or small molecules. DNA encoding these proteins are introduced as genes into live animals, plants or microbes, where their activities can be turned on by near-infrared light, controlled by the intensity of light, and turned off by near-infrared light of a different wavelength than the activating light. These proteins can regulate diverse cellular processes with high spatial and temporal precision, in a nontoxic manner, often using external light sources. For example, near-infrared light-activated proteins possessing nucleotidyl cyclase, protein kinase, protease, DNA-binding and RNA-binding activities are useful to control signal transduction, cell apoptosis, proliferation, adhesion, differentiation and other cell processes.

公开(公告)号：US09458449B2

公开(公告)日：2016-10-04

申请号：US14282228

申请日：2014-05-20

Applicant: Kent Kirshenbaum ,  Paul Levine ,  Timothy Craven

Inventor： Kent Kirshenbaum ,  Paul Levine ,  Timothy Craven

IPC: C12N9/96 ,  C07K1/02 ,  C07K1/13 ,  C07K5/083

CPC classification number: C12N9/96 ,  A61K38/00 ,  C07K1/026 ,  C07K1/13 ,  C07K5/0806 ,  C07K5/081 ,  C07K7/06 ,  C07K7/08 ,  C12N9/22

Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.

Abstract translation: 公开了具有以下表示的结构的新型杂化聚合物，其中非生物低聚物，多肽，X，Y和R 1如本文所述。 还描述了通过新的恶唑烷基化合物制备杂化聚合物的方法。

公开(公告)号：US20160263234A1

公开(公告)日：2016-09-15

申请号：US15065347

申请日：2016-03-09

Applicant: Onyx Therapeutics, Inc.

Inventor： Pasit Phiasivongsa ,  Gary W. Luehr ,  Ge Peng ,  Kolbot By ,  Shabbir T. Anik

IPC: A61K47/48 ,  C07K5/113 ,  A61K38/07

CPC classification number: A61K47/64 ,  A61K38/06 ,  A61K38/07 ,  A61K47/549 ,  A61K47/60 ,  C07K5/06078 ,  C07K5/0806 ,  C07K5/081 ,  C07K5/0821 ,  C07K5/1008 ,  C07K5/1016 ,  C07K5/1021 ,  C07K5/1024 ,  C07K7/06

Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.

Abstract translation: 本公开的特征在于可用作环氧酮蛋白酶抑制剂的前药的化合物。

公开(公告)号：US09422333B2

公开(公告)日：2016-08-23

申请号：US14639228

申请日：2015-03-05

Applicant: Celgene Avilomics Research, Inc.

Inventor： Deqiang Niu ,  Russell C. Petter ,  Lixin Qiao ,  Juswinder Singh

IPC: A61K31/40 ,  C07D209/52 ,  C07K5/087 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/4965 ,  A61K31/506 ,  C07D401/12 ,  C07D403/12 ,  C07K5/078 ,  C07K5/083 ,  C07K5/09 ,  C07K5/097 ,  C07K5/08 ,  A61K38/06 ,  A61K38/07 ,  A61K45/06 ,  C07K5/107 ,  C12N9/50 ,  C12N9/99

CPC classification number: C07K7/06 ,  A61K31/40 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/4965 ,  A61K31/506 ,  A61K38/00 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K45/06 ,  C07D209/52 ,  C07D401/12 ,  C07D403/12 ,  C07K5/06165 ,  C07K5/0802 ,  C07K5/0804 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/081 ,  C07K5/0812 ,  C07K5/0817 ,  C07K5/0819 ,  C07K5/0821 ,  C07K5/0827 ,  C07K5/1016 ,  C12N9/506 ,  C12N9/99 ,  C12Y304/21098

Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

公开(公告)号：US20160166632A1

公开(公告)日：2016-06-16

申请号：US14905179

申请日：2014-07-17

Applicant: ONYX THERAPEUTICS, INC.

Inventor： Shirin Kapur ,  Alana Lerner ,  Christopher J. Kirk ,  Eric Lowe

IPC: A61K38/07 ,  C07K5/083 ,  C07K5/107 ,  A61K45/06 ,  A61K38/06

CPC classification number: A61K38/07 ,  A61K31/426 ,  A61K31/427 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4745 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377 ,  A61K38/04 ,  A61K38/06 ,  A61K38/08 ,  A61K45/06 ,  C07K5/081 ,  C07K5/1016 ,  A61K2300/00

Abstract: This disclosure provides methods of treating a cancer in a patient using a peptide epoxyketone proteasome inhibitor in combination with a PIM kinase inhibitor.

Abstract translation: 本公开提供了使用肽环氧酮蛋白酶体抑制剂与PIM激酶抑制剂组合治疗患者的癌症的方法。

公开(公告)号：US20160152665A1

公开(公告)日：2016-06-02

申请号：US15040228

申请日：2016-02-10

Applicant: The University of Toledo

Inventor： Lirim Shemshedini ,  Shao-Yong Chen ,  Changmeng Cai ,  Chen-Lin Hsieh

IPC: C07K7/08 ,  A61K38/10 ,  A61K38/08 ,  C07K7/06 ,  A61K45/06

CPC classification number: C07K7/08 ,  A61K31/7048 ,  A61K38/00 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K38/10 ,  A61K45/06 ,  C07K5/081 ,  C07K5/1013 ,  C07K5/1016 ,  C07K5/1019 ,  C07K7/06 ,  C12N9/88 ,  C12Y406/01002 ,  A61K2300/00

Abstract: Described herein are compositions and methods useful to treat cancers. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.

Abstract translation: 本文描述的是用于治疗癌症的组合物和方法。 此外，本发明提供筛选测定，诊断测定，预测方法，治疗方法和试剂盒。

公开(公告)号：US09340576B2

公开(公告)日：2016-05-17

申请号：US13909712

申请日：2013-06-04

Applicant: Joseph Moskal

Inventor： Joseph Moskal

IPC: A61K38/07 ,  C07K5/103 ,  C07K5/083 ,  C07K5/097 ,  C07K5/078 ,  A61K45/06

CPC classification number: C07K5/1013 ,  A61K38/07 ,  A61K45/06 ,  C07K5/06139 ,  C07K5/081 ,  C07K5/0821

Abstract: The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist.